| POPRACH, Alexandr, Ondrej FIALA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Radek LAKOMÝ, Katarína PETRÁKOVÁ, Milada ZEMANOVA, Katerina KOPECKOVA, Ondřej SLABÝ, Hana STUDENTOVA, Jindrich KOPECKY, Igor KISS, Jindrich FINEK, Ladislav DUŠEK a Tomas BUCHLER. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. Anticancer Research. Athens: The International Institute of Anticancer Research, 2018, roč. 38, č. 1, s. 449-456. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.12243. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1417179,
author = {Poprach, Alexandr and Fiala, Ondrej and Chloupková, Renata and Melichar, Bohuslav and Lakomý, Radek and Petráková, Katarína and Zemanova, Milada and Kopeckova, Katerina and Slabý, Ondřej and Studentova, Hana and Kopecky, Jindrich and Kiss, Igor and Finek, Jindrich and Dušek, Ladislav and Buchler, Tomas},
article_location = {Athens},
article_number = {1},
doi = {http://dx.doi.org/10.21873/anticanres.12243},
keywords = {Renal cell carcinoma; pazopanib; response; survival; cancer registry},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients},
url = {https://ar.iiarjournals.org/content/38/1/449.long},
volume = {38},
year = {2018}
}
TY - JOUR
ID - 1417179
AU - Poprach, Alexandr - Fiala, Ondrej - Chloupková, Renata - Melichar, Bohuslav - Lakomý, Radek - Petráková, Katarína - Zemanova, Milada - Kopeckova, Katerina - Slabý, Ondřej - Studentova, Hana - Kopecky, Jindrich - Kiss, Igor - Finek, Jindrich - Dušek, Ladislav - Buchler, Tomas
PY - 2018
TI - Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
JF - Anticancer Research
VL - 38
IS - 1
SP - 449-456
EP - 449-456
PB - The International Institute of Anticancer Research
SN - 02507005
KW - Renal cell carcinoma
KW - pazopanib
KW - response
KW - survival
KW - cancer registry
UR - https://ar.iiarjournals.org/content/38/1/449.long
N2 - Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
ER -
POPRACH, Alexandr, Ondrej FIALA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Radek LAKOMÝ, Katarína PETRÁKOVÁ, Milada ZEMANOVA, Katerina KOPECKOVA, Ondřej SLABÝ, Hana STUDENTOVA, Jindrich KOPECKY, Igor KISS, Jindrich FINEK, Ladislav DUŠEK a Tomas BUCHLER. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2018, roč.~38, č.~1, s.~449-456. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.12243.
|
